Stellar Biotechnologies

OverviewSuggest Edit

Stellar Biotechnologies, Inc. specializes in Keyhole Limpet Hemocyanin protein and is focused in the rapidly-evolving field of immunotherapy. KLH is an important immune-stimulating molecule widely used as an active pharmaceutical ingredient in many new immunotherapies, and as an injectable product to assess immune response. This versatile molecule has a long history of safe and effective use across a wide range of disease indications (cancer, inflammatory disease, Alzheimer’s, and immune disorders) and research applications.

TypePublic
Founded1999
HQPort Hueneme, US
Websitestellarbiotechnologies.com

Latest Updates

Employees (est.) (Feb 2019)25(+9%)
Share Price (Jun 2019)$1.1 (-7%)

Key People/Management at Stellar Biotechnologies

Frank R. Oakes

Frank R. Oakes

Chairman of the Board, President and Chief Executive Officer
Gary Koppenjan

Gary Koppenjan

Senior Director of Investor Relations and Communications
Gregory T. Baxter

Gregory T. Baxter

Executive Vice President of Corporate Development
Show more

Stellar Biotechnologies Office Locations

Stellar Biotechnologies has an office in Port Hueneme
Port Hueneme, US (HQ)
332 E Scott St
Show all (1)

Stellar Biotechnologies Financials and Metrics

Stellar Biotechnologies Revenue

Market capitalization (7-Jun-2019)

5.6m

Closing stock price (7-Jun-2019)

1.1
Stellar Biotechnologies's current market capitalization is $5.6 m.
Show all financial metrics

Stellar Biotechnologies Online and Social Media Presence

Embed Graph

Stellar Biotechnologies News and Updates

Edesa Biotech and Stellar Biotechnologies Complete Business Combination

TORONTO, June 7, 2019 /PRNewswire/ -- Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) ("Stellar"), which was completed pursuant to a share exchange...

Stellar Biotechnologies Reports Second Quarter Financial Results

LOS ANGELES, May 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the three and six months ended March 31, 2019...

Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

LOS ANGELES, Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the fiscal year ended September 30, 2018 and...

Stellar Biotechnologies to Present at BlueTech Summit

LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, announced today that Stellar President and CEO Frank R. Oakes will present at the...

Stellar Biotechnologies to Supply KLH to National Institutes of Health

LOS ANGELES, Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, autoimmune disease and cancers, among other diseases, announced today that it...

Stellar Biotechnologies Reports Third Quarter Financial Results

LOS ANGELES, Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today reported financial results for the...

Stellar Biotechnologies Blogs

Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement

LOS ANGELES, March 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, …

Stellar Biotechnologies Reports First Quarter Financial Results

LOS ANGELES, Feb. 5, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the three months ended December 31, 2018 and provided a…

Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

LOS ANGELES, Aug. 28, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today that Stellar CEO and President F…

Stellar Issues Statement on Favorable Clinical Study Results

LOS ANGELES, July 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines, today issued a statement on the favorable Phase 2b study results published by Neovacs, S.A., a customer and join…

Stellar Biotechnologies Frequently Asked Questions

  • When was Stellar Biotechnologies founded?

    Stellar Biotechnologies was founded in 1999.

  • Who are Stellar Biotechnologies key executives?

    Stellar Biotechnologies's key executives are Frank R. Oakes, Gary Koppenjan and Gregory T. Baxter.

  • How many employees does Stellar Biotechnologies have?

    Stellar Biotechnologies has 25 employees.

  • Who are Stellar Biotechnologies competitors?

    Competitors of Stellar Biotechnologies include Biogen, MyoKardia and Ironwood Pharmaceuticals.

  • Where is Stellar Biotechnologies headquarters?

    Stellar Biotechnologies headquarters is located at 332 E Scott St, Port Hueneme.

  • Where are Stellar Biotechnologies offices?

    Stellar Biotechnologies has an office in Port Hueneme.

  • How many offices does Stellar Biotechnologies have?

    Stellar Biotechnologies has 1 office.